Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 5/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.51 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2628867 | 0.88 | CYP2C9 (0.61) | CYP2C9CYP3A4CYP2C19CYP2D6CYP1A2 | |
| SCHEMBL2629183 | 0.88 | CYP2C9 (0.59) | CYP2C9CYP3A4CYP2C19CYP2D6CYP1A2 | |
| SCHEMBL2628889 | 0.88 | CYP2C9 (0.59) | CYP2C9CYP3A4CYP2C19CYP2D6CYP1A2 | |
| SCHEMBL12649356 | 0.88 | CYP2C9 (0.61) | CYP2C9CYP3A4CYP2C19CYP2D6CYP1A2 | |
| SCHEMBL1763529 | 0.86 | CYP2D6 (0.60) | CYP2C9CYP3A4CYP2C19CYP2D6CYP1A2 | |
| SCHEMBL1763433 | 0.86 | CYP2D6 (0.60) | CYP2C9CYP3A4CYP2C19CYP2D6CYP1A2 | |
| SCHEMBL7679024 | 0.86 | CYP2D6 (0.51) | CYP2C9CYP3A4CYP2C19CYP2D6CYP1A2 | |
| SCHEMBL2628887 | 0.86 | CYP2C9 (0.59) | CYP2C9CYP3A4CYP2C19CYP2D6CYP1A2 | |
| SCHEMBL2629102 | 0.85 | CYP3A4 (0.56) | CYP2C9CYP3A4CYP2C19CYP2D6CYP1A2 | |
| SCHEMBL14194601 | 0.85 | CYP2C9 (0.56) | CYP2C9CYP3A4CYP2C19CYP2D6CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2975038-B1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | VIIV HEALTHCARE UK(NO 4) LTD (GB) | 2017-07-12 | — | — | EP | disclosed |
| EP-2975038-B1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | VIIV HEALTHCARE UK(NO 4) LTD (GB) | 2017-07-12 | — | — | EP | disclosed |
| US-20160207918-A1 | SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2016-07-21 | — | — | US | disclosed |
| US-20160207918-A1 | SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2016-07-21 | — | — | US | disclosed |
| US-20160152615-A1 | PRODRUGS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2016-06-02 | — | — | US | disclosed |
| US-20160152615-A1 | PRODRUGS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2016-06-02 | — | — | US | disclosed |
| US-20160152615-A1 | PRODRUGS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2016-06-02 | — | — | US | disclosed |
| US-20160075703-A1 | SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2016-03-17 | — | — | US | disclosed |
| US-20160075703-A1 | SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2016-03-17 | — | — | US | disclosed |
| EP-2975038-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | Bristol-Myers Squibb Company (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20030207910-A1 | Treatment of HIV and AIDS | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2003-11-06 | — | — | US | disclosed |
| US-6632819-B1 | HIV and AIDS | BRISTOL-MYERS SQUIBB COMPANY | 2003-10-14 | — | — | US | disclosed |
| US-20030181463-A1 | Antiviral azaindole derivatives | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2003-09-25 | — | — | US | disclosed |
| US-20030069266-A1 | Aids therapy | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2003-04-10 | — | — | US | disclosed |
| EP-1257276-A1 | ANTIVIRAL AZAINDOLE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-11-20 | — | — | EP | disclosed |
| US-6476034-B2 | AIDS THERAPY | BRISTOL-MYERS SQUIBB COMPANY | 2002-11-05 | — | — | US | disclosed |
| US-20020119982-A1 | Antiviral azaindole derivatives | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2002-08-29 | — | — | US | disclosed |
| WO-2002062423-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-08-15 | — | — | WO | disclosed |
| US-20020061892-A1 | Antiviral azaindole derivatives | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2002-05-23 | — | — | US | disclosed |
| WO-2001062255-A1 | ANTIVIRAL AZAINDOLE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119982-A1 | Antiviral azaindole derivatives | ZC3HAV1, MAVS, AZI2 | CYP2C9 3477/4885CYP3A4 491/4885CYP2C19 3101/4885 |
| US-20160152615-A1 | PRODRUGS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | ITPA, IMPDH2, IDO1 | CYP2C9 905/4885CYP3A4 121/4885CYP2C19 487/4885 |
| US-20020061892-A1 | Antiviral azaindole derivatives | ZC3HAV1, MAVS, AZI2 | CYP2C9 3477/4885CYP3A4 491/4885CYP2C19 3101/4885 |
| US-20160075703-A1 | SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | ITPA, IDO1, IDO2 | CYP2C9 1182/4885CYP3A4 162/4885CYP2C19 592/4885 |
| US-20030069266-A1 | Aids therapy | ENTPD5, CCR5, ITPA | CYP2C9 2580/4885CYP3A4 363/4885CYP2C19 1137/4885 |
| US-20160207918-A1 | SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | PREP, PEPD, DNPEP | CYP2C9 1411/4885CYP3A4 175/4885CYP2C19 710/4885 |
| US-20030207910-A1 | Treatment of HIV and AIDS | CD4, CCR5, IDO1 | CYP2C9 1831/4885CYP3A4 138/4885CYP2C19 797/4885 |
| US-20030181463-A1 | Antiviral azaindole derivatives | ZC3HAV1, MAVS, AZI2 | CYP2C9 3477/4885CYP3A4 491/4885CYP2C19 3101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.